0.0004USD0.00%Mkt Cap: 10732 USDP/E: —Last update: 2026-05-25
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor a…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap10.73K USD
Enterprise Value1.96M USD
Revenue (TTM)386.00K USD
Gross Profit-88.25M USD
Net Income (TTM)-164.57M USD
Revenue/Share0.0100 USD
Last Price0.0004 USD
Fiscal Year EndDec 2023
MR QuarterSep 2024
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA-0.02
EV/Revenue5.07
P/S0.01
P/B-0.00
EPS (TTM)-3.07
EPS (Forward)-2.61
52W Range
0.00011% of range0.0400
52W High0.0400 USD
52W Low0.0001 USD
Profitability
Gross Margin0.00%
Oper. Margin-28891.71%
EBITDA Margin0.00%
Profit Margin-1656.34%
ROE-987.72%
ROA-97.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.71M USD
CapEx (TTM)272.00K USD
FCF Margin-15011.01%
FCF Yield-539904.03%
Net Debt1.95M USD
Net Debt/EBITDA-0.02
Balance Sheet
Debt/Equity3.73
Current Ratio2.25
Quick Ratio2.05
Book Value/Sh-0.4150 USD
Cash/Share2.172 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateSep 19, 2022
Analyst Consensus
Rating—
Target (Mean)8.750 USD
Target Range4.000 USD – 20.00 USD
# Analysts4
Ownership
Shares Out.26.83M
Float26.82M
Insiders0.15%
Institutions9.62%
Short Interest
Short Ratio0.8d
Short % Float3.81%
Short % Out.3.50%
Shares Short939.58K
Short (prev mo.)723.20K
Technical
SMA 500.0003 (+50.4%)
SMA 2000.0009 (-55.3%)
Beta1.26
S&P 52W Chg28.31%
Avg Vol (30d)7.99K
Avg Vol (10d)13.80K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—